Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer

Next Previous
Trial Profile

A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms VANILLA
  • Sponsors Sanofi

Most Recent Events

  • 05 Oct 2021 This trial has been completed in Spain and France (End Date: 28 Oct 2009), according to European Clinical Trials Database record.
  • 05 Jun 2018 Results of prognostic nomogram using training and validation cohorts from (NCT00844649, NCT01124786 and NCT00574275) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
  • 20 Jan 2018 Results of pool data from the comparator arm of three clinical trails (NCT00844649, NCT01124786 and NCT00574275) in MPC treated with gemcitabine as first-line chemotherapy, were presented at the 2018 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top